

Supplementary Table 1. Univariable analyses of clinical features with overall and complete response rates.

Characteristics	ORR			CR		
	OR	95% CI	P	OR	95% CI	P
Age in deciles	0.72	0.51-1.01	0.060	0.91	0.60-1.40	0.65
Male sex	1.02	0.35-3.24	0.97	1.21	0.31-5.97	0.79
Histology						
DLBCL	—	—	Ref	***	***	0.21
HGBL	2.00	0.26-10.96	0.45			
FL	7.00	0.25-193.94	0.19			
PMBCL	11.67	2.31-70.59	0.004			
Transformed lymphomas	1.00	0.14-4.94	1			
THRLBCL	3.50	0.42-22.62	0.20			
Non-GCB cell of origin	1.75	0.47-6.75	0.40	1.89	0.38-10.33	0.43
Double expressor lymphoma	***	***	0.57	not performed		
Double hit lymphoma	***	***	0.32	not performed		
History of primary refractory disease	1.22	0.43-3.53	0.71	0.59	0.14-2.21	0.44
Previous transplant	1.37	0.43-4.07	0.58	1.11	0.22-4.40	0.89
Receipt of CPI prior to CAR-T	0.76	0.04-5.17	0.81	1.62	0.08-11.68	0.67
Receipt of BTK inhibitors prior to CAR-T	0.54	0.03-3.32	0.57	***	***	0.59
Receipt of immunomodulatory agents prior to CAR-T	***	***	0.035	***	***	0.20
Receipt of bridging therapy prior to CAR-T	0.62	0.21-1.88	0.38	1.02	0.26-5.03	0.98
CAR-T product administered						
axicabtagene ciloleucel	—	—	Ref	***	***	0.20
lisocabtagene maraleucel	2.60	0.66-9.84	0.16			
tisagenlecleucel	1.50	0.40-5.34	0.53			
other	5.71	0.21-156.52	0.24			
Grade of CRS during CAR-T	***	***	0.32	***	***	0.66
Grade of ICANS during CAR-T	***	***	0.31	***	***	0.68
Relapse type						
Early relapse	—	—	Ref	—	—	Ref
Late relapse	3.23	0.85-11.51	0.072	3.40	0.64-15.27	0.12
Stage at relapse after CAR-T						
I	—	—	Ref	—	—	Ref
II	1.23	0.13-27.84	0.87	0.53	0.04-13.19	0.64
III	0.40	0.01-11.80	0.55	0.40	0.01-11.80	0.55
IV	1.00	0.13-20.60	1	0.40	0.05-8.62	0.45
Extranodal disease at relapse after CAR-T						
No	—	—	Ref	—	—	Ref
Yes, only 1 site	1.52	0.35-7.94	0.59	4.04	0.59-80.57	0.22
Yes, > 1 site	1.88	0.47-9.42	0.40	1.97	0.23-41.27	0.57
Bulky disease at relapse after CAR-T	0.79	0.20-2.57	0.72	0.75	0.11-3.40	0.73
CNS involvement at time of relapse after CAR-T	0.65	0.03-4.17	0.70	***	***	1
CPI type received	***	***	0.94	***	***	1
Concurrent therapeutics with CPI	1.21	0.38-3.63	0.73	0.91	0.18-3.57	0.80
Grade ≥3 AEs due to CPI	0.98	0.21-3.59	0.98	0.52	0.03-3.09	0.54

*** = Fisher's exact test performed due to variables with zero individuals in at least one strata.

Supplementary Figure 1. Progression-free survival (PFS) in a combined cohort of patients with DLBCL and HGBL by type of CAR-T product received.

